In September-begin October we had our yearly elections for Council Members. Three ordinary Council positions were available and the position of President Elect.
In order to faclitate the need to provide coherent instructions and guidance to EAMBES members on how to properly engage with forthcoming Horizon 2020 calls- We would like to draw your attention to the following past and future events which may be of interest:
On the occasion of the high level conference on "The Future of Europe is Science" that is taking place in Lisbon, the European Commission launched the report of the Science and Technology Advisory Council (STAC). Under the title "The Future of Europe is Science", it outlines some key opportunities for Europe that could be provided by science and technology, looking ahead to the year 2030. The report, of interest for various clients, is structured around citizens' priorities, as identified by the Special Eurobarometer 419 on "Public perceptions of Science, Research and Innovation" survey published on 6 October, which found that health and medical care were seen by 55% of European citizens as the top priorities for science and technology innovation over the next fifteen years.
The Public Health bill for 2015, based on the National Health Strategy, has been presented by the Minister of Health Marisol Touraine in October. The bill was introduced in the Parliament on the 15 October and publishedon the 27 October 2014.
I. Concessions granted by Commission President elect as new European Commission approved by the European Parliament
On October 22nd 2014 the European Parliament (EP) approved the new European Commission led by Mr. Jean-Claude Juncker. Members of the European Parliament (MEP) backed the new Commission with 423 votes in favour, 209 votes against and 67 abstentions. The EPP, S&D and ALDE groups had given their support to the Commissioners, whereas the Greens, GUE/NGL, Eurosceptic and far-right MEPs had all announced they would vote against. The abstentions were from the British Conservatives and their Polish and German ECR group allies.
The Conservatives and the Liberals defeat the Socialists in French Senatorial elections - 28 September 2014
The Senate elections were held on the 28 September in France and were marked by the defeat of the Socialist Party, the current Government majority. The Conservatives and the Liberals now hold the majority in the Senate. Following this week’s victory, the Conservatives and Liberals now hold the absolute majority, with 188 Senators. The Socialists hold 151 seats. These results mark the third electoral defeat of the Government majority in 6 months (municipal elections, European elections and Senate elections). There are now 2 senators from the Front National (nationalist party).
Lost in translation? How to get healthcare biotech from lab to clinic for a healthier wealthier Europe
A policy roundtable discussion entitled “Lost in Translation? How to get healthcare biotech from lab to clinic for a healthier wealthier Europe” will take place in the European Parliament in Brussels on the 9 October 2014. The event is being hosted by European Science in Business with the support of the European Association of Bio industries (EuropaBio)
European Researchers’ Night aims to heighten awareness of careers in research amongst younger generations
The ninth annual European Researchers’ night- the Europe-wide initiative took place on Friday the 26 September 2014. The annual event was launched in 2005 in 20 cities in 15 countries. The events are selected through open and transparent competition following a public call for bids. Whilst the event placed particular emphasis on the need to enhance the public profile of researchers and to stimulate interest in research careers, especially amongst young people it offered ample opportunity to network with fellow researchers in a relaxing and less formal environment.
Maintenance of “European model" of health discussed during EP Hearing for Commissioner-designate for Trade, Ms. Cecilia Malmström
The European Parliament commenced its hearings of Commission nominees on 29 September with the hearing on the Commissioner-designate for Trade, Ms. Cecilia Malmström (Sweden) -current Commissioner for Home Affairs- in the INTA Committee. Ms. Malmström as the Commissioner for Trade would be responsible for the Transatlantic Trade and Investment Partnership (TTIP) negotiations. The hearing was eagerly anticipated due to the controversy around certain aspects of TTIP, and specifically around the 'investor-state dispute settlement' (ISDS) -a mechanism that would allow foreign investors to take national governments to court if they believe they have been treated in a way that breaches free trade deals-. The controversy followed Ms. Malmström's written response to initial questions from MEPs, suggesting that she rejected the need for ISDS in TTIP.
On 16 September 2014, a debate was held in the European Parliament on structural funding for Horizon 2020 during which new budgetary issues were highlighted. The Commission will see a shortfall of 40% of funding commitments to researchers which could lead to the Commission failing to make good on their contractual arrangements and putting many research projects under threat.
On 10 September 2014 together with the announcement of a change in Commission portfolios, came President of the Commission, Jean-Claude Junker’s list of Commissioners-designate.
On 10 September 2014, President of the European Commission Jean Claude Juncker announced a reorganisation of certain key portfolios.
On the 16 September 2014, the European Commission presented the ERA progress report. It shows that the ERA partnership between Member States, research stakeholders and the Commission has made good progress in delivering European Research Area (ERA), and that the conditions for achieving it identified in 2012 (see the Commission’s Communication - A Reinforced European Research Area Partnership for Excellence and Growth) are in place at the European level.
The hearings of the Dr. Vytenis Andrukaitis, Commissioner Designate for Health and Food Safety took place in the Environment, Public Health and Food Safety (ENVI) today the 30 September 2014. MEP questions and the atmosphere of the debate was largely non-confrontational, indicating a likely endorsement for the candidate. It is interesting to note that Dr. Andriukaitis seemed markedly more confident on human health matters, showing both his professional background and his political experience. His answers on what is now the majority of his portfolio, regarding food safety and animal matters, tended to be more often vague.
IMI 2 will hold an Open Info Day on its IMI 2-Call 1 in Brussels, Belgium on Tuesday 30 September 2014. The deadline for registration is the 23 September 2014.
On behalf of the President of EAMBES, Prof. Birgit Glasmacher, we hereby cordially invite you to attend the next GC and GA Meeting, organized during the 48th DGBMT Annual Conference (within VDE) in Hannover, Germany (www.bmt2014.de).
Deadline for this call is extended to October 15th
Just a quick reminder that the NBC16/MTD10 in Goteborg is approaching.
On her website on 17 September 2014, Mrs. Willmott stated that “we must ensure the industry is transparent and works in the interest of patients. This legislation will go a long way to achieving that and I look forward to taking it further in the coming months” She also expressed concern that the responsibility for medical devices policy will not fall under the auspices of DG Enterprise, following a decision by Mr. Junker which is being increasingly criticized by key EU stakeholders. As rapporteur for the Clinical Trials Regulation and a long-standing health-focused MEP, Mrs. Willmott was one of three main MEPs tipped to be the next Rapporteur of the MDR who will take over from ousted MEP Ms. Dagmar Roth-Behrendt (S&D, Germany). The other two potential MEPs that were suggested were Ms. Linda McAvan (S&D, UK) and Ms. Christel Schaldemose (S&D, Denmark). While Ms. Willmott did not take a central role in the discussions on the Medical Devices Regulation during the previous Parliamentary term, her focus during the Clinical Trials Regulation was on improving transparency and safety for patients.
Also on behalf of Adriana Velazquez Berumen of the WHO we cordially invite you and your colleagues in the development of a WHO global repository of Biomedical Engineering and its role on medical devices field, specifically on: country profiles, academic institutions, government, and professional organizations. (This news item is an adaptation of the mail she send out earlier this year)